Celltrion keeps ECM ticking

摘要

South Korea's buoyant equity capital markets look set for a further boost from the Wltrn (US$883m) listing of biopharmaceutical distributor CELLTRION HEALTHCARE. The sales and marketing company, which specialises in biosimilars, was on track to price its Korea Exchange listing around the top of the target range, according to guidance sent to investors on Friday.